Integrated wearable-based perioperative care for NSCLC patients undergoing thoracic surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, single-center trial will enroll adults with NSCLC scheduled for elective VATS lobectomy or segmentectomy. Participants are assigned to receive either standard perioperative care plus a digital, wearable-supported rehabilitation program or standard care alone. The intervention includes prehabilitation with aerobic, respiratory muscle, and resistance training, plus continuous perioperative monitoring and home-based digital rehabilitation guided by wearable devices and remote platforms. Outcomes focus on short-term postoperative pulmonary function, functional recovery, and clinical results. The study aims to validate an integrated wearable-based perioperative management system in a real-world setting at a single center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years and ≤85 years
* Pathologically confirmed primary non-small cell lung cancer (NSCLC)
* Scheduled to undergo elective curative-intent thoracoscopic lobectomy or segmentectomy
* Able to independently operate a smartphone and wearable device, or able to do so with caregiver assistance
* Willing to comply with study procedures and follow-up requirements
* Provided written informed consent prior to participation

Exclusion Criteria:

* Preoperative long-term home oxygen therapy or severe resting respiratory failure
* Presence of severe or uncontrolled cardiopulmonary disease, cerebrovascular disease, hepatic insufficiency, or renal insufficiency
* Severe comorbid conditions that significantly limit physical activity or adherence to rehabilitation
* Known or suspected allergy to materials used in wearable devices or medical adhesives
* Any other condition that, in the judgment of the investigators, makes the participant unsuitable for study participation

Where it's running

• West China Hospital
  Chengdu, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Wireless home prehabilitation for older adults with NSCLC awaiting lung surgery

  This study tests whether a personalized home exercise program guided by wearable devices can improve lung function for older NSCLC patients preparing for curative lung surgery.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07809763

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• NSCLC biomarker study using tumor and blood samples to link genetics with prognosis and immunotherapy response

  Researchers will test tumor tissue and blood from about 300 NSCLC patients to find genomic and immune markers that predict prognosis and response to immunotherapy.

  Recruiting at 20 sites Hellenic Cooperative Oncology Group · Limassol and 19 other locations · NCT07900581

• AirGo Respiratory Monitoring During Lung Resection

  Patients undergoing lung resection will wear the AirGo device to continuously monitor breathing before and after surgery to see if it helps track ventilation alongside standard checks.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07838025

• Frailty-focused prehabilitation before heart surgery

  This study tests a home-based, frailty-tailored prehabilitation program for adults 65+ waiting 5 weeks or more for heart surgery to see if it improves fitness, frailty, heart-related function, nutrition, inflammation, quality of life, and hospital outcomes.

  Recruiting The University of Hong Kong · Hong Kong · NCT07824700

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.